# Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Source: https://onco.cc/trials/nct05703971/  
OnCo record `nct05703971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atezolizumab in small-cell lung cancer, run by Genprex, Inc., now recruiting.

## Summary

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients is a phase 1/2 interventional study registered as NCT05703971 by Genprex, Inc., with 62 participants planned, started 2024-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: quaratusugene ozeplasmid, atezolizumab. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05703971
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Sponsor: Genprex, Inc.
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05703971: https://clinicaltrials.gov/study/NCT05703971

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- companies: [Genprex](https://onco.cc/companies/genprex/)

---
JSON: https://onco.cc/api/v1/entities/nct05703971.json